Apremilast - CAS 608141-41-9
Catalog number:
608141-41-9
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C22H24N2O7S
Molecular Weight:
460.5
COA:
Inquire
Targets:
PDE4
Description:
Apremilast (CC-10004)is an orally available small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast specifically inhibits PDE4 and inhibits spontaneous production of TNF-alpha from human rheumatoid synovial cells.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
CC-10004
MSDS:
Inquire
1.Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.
Nguyen CM, Leon A, Danesh M, Beroukhim K, Wu JJ, Koo J. J Drugs Dermatol. 2016 Mar 1;15(3):272-6.
INTRODUCTION: A significant portion of patients with psoriasis have scalp and nail involvement. It has been reported that 40% to 45% of patients with psoriasis have nail psoriasis, and up to 80% have scalp involvement. Nail and scalp psoriasis have often been found to be difficult to treat, due to the poor penetration and poor compliance of topical medication. Oral and biologic therapies have shown significant efficacy but often with undesirable side effects. Herein, we analyze the efficacy of apremilast, an oral phosphodiesterase-4 (PDE-4) inhibitor, in the treatment of nail and scalp psoriasis at 16-, 32-, and 52 weeks.<br/>
2.Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
Bissonnette R1, Pariser DM2, Wasel NR3, Goncalves J4, Day RM4, Chen R4, Sebastian M5. J Am Acad Dermatol. 2016 Mar 24. pii: S0190-9622(16)01400-6. doi: 10.1016/j.jaad.2016.02.1164. [Epub ahead of print]
BACKGROUND: Difficult-to-treat palmoplantar psoriasis has a disproportionately negative impact on quality of life.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related PDE4 Products


CAS 1415560-64-3 GSK256066 2,2,2-trifluoroacetic acid

GSK256066 2,2,2-trifluoroacetic acid
(CAS: 1415560-64-3)

GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, &gt;380,000-fold selectivity versus PDE1/2/3/5/6 and &gt;2500-fold...

NVP-ABE-171
(CAS: 426268-06-6)

NVP-ABE171 is a potent and novel phosphodiesterase 4 inhibitor with anti-inflammatory activities inhibited the activity of phosphodiesterase 4A, 4B, 4C, and 4D ...

CP-220629
(CAS: 162141-96-0)

CP-220629, a Pyrazolopyridin derivative, has been found to be a Type 4 cyclic nucleotide phosphodiesterase inhibitor that was once studied as an anti-inflammato...

CAS 101975-10-4 Zardaverine

Zardaverine
(CAS: 101975-10-4)

Zardaverine is a newly developed dual-selective PDE3/4 inhibitor with IC50 values of 0.5 μM and 0.8 μM respectively.

CI-1044
(CAS: 197894-84-1)

CI-1044, a selective PDE4 inhibitor, inhibits in vitro LPS-induced TNF-alpha release in whole blood from COPD patients better than rolipram and cilomilast and s...

CAS 346629-30-9 MK-0359

MK-0359
(CAS: 346629-30-9)

MK-0359 is a selective and potent oral PDE4 inhibitor with in vivoefficacy in animal models of asthma and cognition.

CAS 162401-32-3 Roflumilast

Roflumilast
(CAS: 162401-32-3)

Roflumilast has antiinflammatory effects and is under development as an orally administered drug for the treatment of inflammatory conditions of the lungs such ...

GSK-356278
(CAS: 720704-34-7)

GSK-356278 is a selective Type 4 cyclic nucleotide phosphodiesterase inhibitor. It shows anxiolytic and cognition-enhancing effects and it has the ability to el...

MK0873
(CAS: 500355-52-2)

MK0873 is a phosphodiesterase 4 (PDE4) inhibitor. It has shown as an innovative tool to design topical formulation to achieve desired pharmacokinetics in humans...

CAS 153259-65-5 Cilomilast

Cilomilast
(CAS: 153259-65-5)

Selective phosphodiesterase 4 (PDE4) inhibitor. Antiasthmatic; used in treatment of chronic obstructive pulmonary disease.

CAS 418794-42-0 Ronomilast

Ronomilast
(CAS: 418794-42-0)

Ronomilast is type 4 cyclic nucleotide phosphodiesterase inhibitor for the treatment of chronic obstructive pulmonary disease (COPD).

CAS 608141-41-9 Apremilast

Apremilast
(CAS: 608141-41-9)

Apremilast (CC-10004)is an orally available small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast specifically inhibits PDE4 and inhibits spontaneo...

L-869298
(CAS: 362718-73-8)

L-869298 is a high potent and selective PDE4 inhibitor, acts as a Type 4 cyclic nucleotide phosphodiesterase inhibitor.

AN3199
(CAS: 1187187-10-5)

AN3199, a PDE4 inhibitor, was once studied as an anti-inflammatory agent. IC50: 94.5 nM

CAS 166741-91-9 Tilivapram

Tilivapram
(CAS: 166741-91-9)

Tilivapram, a pyridine derivative, has been found to be a phosphodiesterase IV inhibitor that could probably be used in studying its bioactivities in sorts of a...

CAS 85416-73-5 S- (+)-Rolipram

S- (+)-Rolipram
(CAS: 85416-73-5)

S-(+)-Rolipram inhibits human monocyte cyclic AMP-specific PDE4 with IC50 of 0.75 μM, has anti-inflammatory and anti-depressant activity in the central nervous ...

CAS 778576-62-8 Oglemilast

Oglemilast
(CAS: 778576-62-8)

Oglemilast is a potent PDE4 inhibitor and under clinical studies in the treatment of allergen-induced asthma.

CAS 61413-54-5 Rolipram

Rolipram
(CAS: 61413-54-5)

Rolipram is a selective PDE4-inhibitor and an anti-inflammatory agent.

CP-671305
(CAS: 445295-04-5)

CP-671305 is a potent and selective inhibitor of PDE4.

CAS 801312-28-7 GSK256066

GSK256066
(CAS: 801312-28-7)

GSK256066 is a selective PDE4B(equal affinity to isoforms A-D) inhibitor with IC50 of 3.2 pM, >380,000-fold selectivity versus PDE1/2/3/5/6 and >2500-fold selec...

Chemical Structure

CAS 608141-41-9 Apremilast

Quick Inquiry

Verification code

Featured Items